PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021
Study findings highlight the increased use of PD-L1 testing over the years from 2017 to 2020 and recent changes in therapy, with decreased use of chemotherapy and increased use of ICI-chemotherapy combinations during the study in each histomolecular group. Moreover, we observed improvements in survival for patients with metastatic NSCLC relative to historical real-world data.
Authors
- Vadeerat Rinsurongkawong (ORCID: https://orcid.org/0009-0002-1667-6884)
- Don L. Gibbons (ORCID: https://orcid.org/0000-0003-2362-3094)
- Melissa L. Santorelli (ORCID: https://orcid.org/0000-0002-2964-7292)
- Waree Rinsurongkawong (ORCID: https://orcid.org/0000-0002-8750-7562)
- Mehmet Altan (ORCID: https://orcid.org/0000-0001-9229-156X)
- Thomas W. Burke (ORCID: https://orcid.org/0000-0003-0592-5822)
- John Victor Heymach (ORCID: https://orcid.org/0000-0001-9068-8942)
- Ara Asadur Vaporciyan (ORCID: https://orcid.org/0000-0002-2060-3584)
- Loretta A. Williams (ORCID: https://orcid.org/0000-0003-2788-657X)
- Dawen Sui (ORCID: https://orcid.org/0000-0002-8956-478X)
- Cai Xu (ORCID: https://orcid.org/0000-0002-1412-4229)
- Darcy Ponce (ORCID: https://orcid.org/0000-0001-6916-2532)
- Donna Malveaux
- Jianjun Zhang (ORCID: https://orcid.org/0000-0001-7872-3477)
- J. Jack Lee (ORCID: https://orcid.org/0000-0001-5469-9214)
- George R. Simon (ORCID: https://orcid.org/0000-0002-3894-0773)
- Saliha T. Sulihem
Institutions
- OhioHealth (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal of Immunotherapy and Precision Oncology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.36401/jipo-24-26
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Celgene
- Society for Immunotherapy of Cancer
- Novocure
- Jounce Therapeutics
- Innovent Biologics
- Ribon Therapeutics
- NGM Biopharmaceuticals
- Astellas Pharma
- Genentech
- EMD Serono
- University of Texas MD Anderson Cancer Center